Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Multi-Modality Imaging in Vasculitis
Allam, Mohamed , Ali, Nima Baba , Mahmoud, Ahmed , Scalia, Isabel G. , Farina, Juan M. , Abbas, Mohammed Tiseer , Pereyra, Milagros , Kamel, Moaz, Awad, Kamal A., Wang, Yuxiang , Barry, Timothy , Huang, Steve S. , Yang, Ming , Jokerst, Clinton, Martinez, Felipe , Arsanjani, Reza , Awad, Kamal , Allam, Mohamed N , Baba Ali, Nima, Mahmoud, Ahmed K , Kamel, Moaz A, Nguyen, Ba D. , Martinez, Felipe , Arsanjani, Reza , Farina, Juan M , Pereyra, Milagros , Scalia, Isabel G , Abbas, Mohammed Tiseer , Awad, Kamal

Mayo Clinic

Diagnostics | April 18, 2024 | Volume: 14 | Issue: 8 | Pages: 838

10.3390/diagnostics14080838 | PMID 38667483 Get It

Systemic vasculitides are a rare and complex group of diseases that can affect multiple organ systems. Clinically, presentation may be vague and non-specific and as such, diagnosis and subsequent management are challenging. These entities are typically classified by the size of vessel involved, including large-vessel vasculitis (giant cell arteritis, Takayasu’s arteritis, and clinically isolated aortitis), medium-vessel vasculitis (including polyarteritis nodosa and Kawasaki disease), and small-vessel vasculitis (granulomatosis with polyangiitis and eosinophilic granulomatosis with polyangiitis). There are also other systemic vasculitides that do not fit in to these categories, such as Behcet’s disease, Cogan syndrome, and IgG4-related disease. Advances in medical imaging modalities have revolutionized the approach to diagnosis of these diseases. Specifically, color Doppler ultrasound, computed tomography and angiography, magnetic resonance imaging, positron emission tomography, or invasive catheterization as indicated have become fundamental in the work up of any patient with suspected systemic or localized vasculitis. This review presents the key diagnostic imaging modalities and their clinical utility in the evaluation of systemic vasculitis.
The ARPKD Protein DZIP1L Regulates Ciliary Protein Entry by Modulating the Architecture and Function of Ciliary Transition Fibers
Chen, Huicheng , Wu, Zhimao, Yan, Ziwei , Chen, Chuan , Zhang, Yingying , Wang, Qiaoling, Gao, Yuqing, Ling, Kun , Hu, Jinghua , Wei, Qing , Chen, Chuan , Wang, Qiaoling, Gao, Yuqing

Mayo Clinic

Advanced Science | April 18, 2024 | Volume: 11 | Issue: 24 | Pages: No page available

10.1002/advs.202308820 | PMID 38634253 Get It

AbstractServing as the cell's sensory antennae, primary cilia are linked to numerous human genetic diseases when they malfunction. DZIP1L, identified as one of the genetic causes of human autosomal recessive polycystic kidney disease (ARPKD), is an evolutionarily conserved ciliary basal body protein. Although it has been reported that DZIP1L is involved in the ciliary entry of PKD proteins, the underlying mechanism remains elusive. Here, an uncharacterized role of DZIP1L is reported in modulating the architecture and function of transition fibers (TFs), striking ciliary base structures essential for selective cilia gating. Using C. elegans as a model, C01G5.7 (hereafter termed DZIP‐1) is identified as the sole homolog of DZIP1L, which specifically localizes to TFs. While DZIP‐1 or ANKR‐26 (the ortholog of ANKRD26) deficiency shows subtle impact on TFs, co‐depletion of DZIP‐1 and ANKR‐26 disrupts TF assembly and cilia gating for soluble and membrane proteins, including the ortholog of ADPKD protein polycystin‐2. Notably, the synergistic role for DZIP1L and ANKRD26 in the formation and function of TFs is highly conserved in mammalian cilia. Hence, the findings illuminate an evolutionarily conserved role of DZIP1L in TFs architecture and function, highlighting TFs as a vital part of the ciliary gate implicated in ciliopathies ARPKD.
Spontaneous coronary artery dissection outcomes among pregnant vs. non-pregnant women
Krittanawong, Chayakrit , Patel, Neelkumar , Maitra, Neil Sagar , Khawaja, Muzamil, Shani, Jacob, Frankel, Robert , Sharma, Samin K. , Jneid, Hani , Krittanawong, Chayakrit , Bandyopadhyay, Dhrubajyoti , Khawaja, Muzamil , Wang, Zhen , Alam, Mahboob

Mayo Clinic

European Heart Journal: Acute Cardiovascular Care | April 17, 2024 | Volume: 13 | Issue: 5 | Pages: 423-428

10.1093/ehjacc/zuae042 | PMID 38630619 Get It

Abstract Aims Spontaneous coronary artery dissection (SCAD) has become increasingly recognized. It accounts for <1-4% of acute coronary syndrome presentations. Overall, however, it makes up over 40% of pregnancy-associated myocardial infarction. Furthermore, pregnancy-associated spontaneous coronary artery dissection (P-SCAD) is described to have a greater degree of clinical manifestations, including left ventricular dysfunction, shock, and left main or multivessel involvement. The findings are disconcerting, though many studies evaluating P-SCAD are based on case series data or are single centre studies. Methods and results The aim of this study was to evaluate a larger national dataset to evaluate the outcomes of SCAD and specifically P-SCAD in an attempt to better characterize the severity and clinical nature of this condition. To conduct this study, we analysed the National Readmission Database from January 2016 to December 2020. Propensity matching was done using the Greedy 1:1 method. Multivariate logistics and time-to-event Cox regression analysis models were built by including all confounders significantly associated with the outcome on univariable analysis with a cut-off P-value of 0.2. In multivariate regression analysis, P-SCAD patients had a non-propensity matched odds ratio (OR) of 0.21 (0.3-1.54, P = 0.123) of dying and a propensity matched OR of 0.11 (0.02-0.61, P = 0.012) of dying. Thirty-day readmission rate for P-SCAD was 15.8% (n = 93) and for non-pregnant spontaneous coronary artery dissection (NP-SCAD) was 11.2% (n = 2286); non-propensity matched OR for readmission for PSCAD patients was 1.68 (1.24-2.29, P = 0.001) and propensity matched OR was 3.39 (1.93-5.97, P < 0.001). Conclusion Among hospitalized patient, P–SCAD was associated with similar clinical outcomes and reduced incidence of death when compared with NP–SCAD, though had higher rates of 30–day readmission. Larger–scale observational data will be needed to ascertain the true incidence of cardiovascular complications as it relates to P–SCAD.
Validation of GPT‐4 for clinical event classification: A comparative analysis with ICD codes and human reviewers
Wang, Yichen , Huang, Yuting , Nimma, Induja R., Pang, Songhan, Pang, Maoyin , Cui, Tao, Kumbhari, Vivek , Huang, Yuting , Wang, Yichen , Cui, Tao

Mayo Clinic

Journal of Gastroenterology and Hepatology | April 17, 2024 | Volume: 39 | Issue: 8 | Pages: 1535-1543

10.1111/jgh.16561 | PMID 38627920 Get It

AbstractBackground and AimEffective clinical event classification is essential for clinical research and quality improvement. The validation of artificial intelligence (AI) models like Generative Pre‐trained Transformer 4 (GPT‐4) for this task and comparison with conventional methods remains unexplored.MethodsWe evaluated the performance of the GPT‐4 model for classifying gastrointestinal (GI) bleeding episodes from 200 medical discharge summaries and compared the results with human review and an International Classification of Diseases (ICD) code‐based system. The analysis included accuracy, sensitivity, and specificity evaluation, using ground truth determined by physician reviewers.ResultsGPT‐4 exhibited an accuracy of 94.4% in identifying GI bleeding occurrences, outperforming ICD codes (accuracy 63.5%, P < 0.001). GPT‐4's accuracy was either slightly lower or statistically similar to individual human reviewers (Reviewer 1: 98.5%, P < 0.001; Reviewer 2: 90.8%, P = 0.170). For location classification, GPT‐4 achieved accuracies of 81.7% and 83.5% for confirmed and probable GI bleeding locations, respectively, with figures that were either slightly lower or comparable with those of human reviewers. GPT‐4 was highly efficient, analyzing the dataset in 12.7 min at a cost of 21.2 USD, whereas human reviewers required 8–9 h each.ConclusionOur study indicates GPT‐4 offers a reliable, cost‐efficient, and faster alternative to current clinical event classification methods, outperforming the conventional ICD coding system and performing comparably to individual expert human reviewers. Its implementation could facilitate more accurate and granular clinical research and quality audits. Future research should explore scalability, prompt and model tuning, and ethical implications of high‐performance AI models in clinical data processing.
Cervical spondylotic myelopathy and driving abilities: defining the prevalence and long-term postoperative outcomes using the Quality Outcomes Database
Agarwal, Nitin , Johnson, Sarah E. , Bydon, Mohamad , Bisson, Erica F. , Chan, Andrew K. , Shabani, Saman , Michalopoulos, Giorgos D. , Lu, Daniel C. , Wang, Michael Y. , Haid, Regis W., Knightly, John J. , Sherrod, Brandon A. , Gottfried, Oren N., Shaffrey, Christopher I. , Virk, Michael S. , Hussain, Ibrahim , Glassman, Steven D. , Shaffrey, Mark E., Foley, Kevin T. , Pennicooke, Brenton , Coric, Domagoj , Slotkin, Jonathan R., Upadhyaya, Cheerag D., Potts, Eric A. , Tumialán, Luis M. , Chou, Dean , Fu, Kai-Ming, Asher, Anthony L. , Mummaneni, Praveen V. , Michalopoulos, Giorgos , Letchuman, Vijay , Lavadi, Raj Swaroop , Goldberg, Jacob L. , Park, Paul

Mayo Clinic

Journal of Neurosurgery: Spine | April 16, 2024 | Volume: 40 | Issue: 5 | Pages: 630-641

10.3171/2023.11.spine23738 | PMID 38364219 Get It

OBJECTIVE Cervical spondylotic myelopathy (CSM) can cause significant difficulty with driving and a subsequent reduction in an individual’s quality of life due to neurological deterioration. The positive impact of surgery on postoperative patient-reported driving capabilities has been seldom explored. METHODS The CSM module of the Quality Outcomes Database was utilized. Patient-reported driving ability was assessed via the driving section of the Neck Disability Index (NDI) questionnaire. This is an ordinal scale in which 0 represents the absence of symptoms while driving and 5 represents a complete inability to drive due to symptoms. Patients were considered to have an impairment in their driving ability if they reported an NDI driving score of 3 or higher (signifying impairment in driving duration due to symptoms). Multivariable logistic regression models were fitted to evaluate mediators of baseline impairment and improvement at 24 months after surgery, which was defined as an NDI driving score < 3. RESULTS A total of 1128 patients who underwent surgical intervention for CSM were included, of whom 354 (31.4%) had baseline driving impairment due to CSM. Moderate (OR 2.3) and severe (OR 6.3) neck pain, severe arm pain (OR 1.6), mild-moderate (OR 2.1) and severe (OR 2.5) impairment in hand/arm dexterity, severe impairment in leg use/walking (OR 1.9), and severe impairment of urinary function (OR 1.8) were associated with impaired driving ability at baseline. Of the 291 patients with baseline impairment and available 24-month follow-up data, 209 (71.8%) reported postoperative improvement in their driving ability. This improvement seemed to be mediated particularly through the achievement of the minimal clinically important difference (MCID) in neck pain and improvement in leg function/walking. Patients with improved driving at 24 months noted higher postoperative satisfaction (88.5% vs 62.2%, p < 0.01) and were more likely to achieve a clinically significant improvement in their quality of life (50.7% vs 37.8%, p < 0.01). CONCLUSIONS Nearly one-third of patients with CSM report impaired driving ability at presentation. Seventy-two percent of these patients reported improvements in their driving ability within 24 months of surgery. Surgical management of CSM can significantly improve patients’ driving abilities at 24 months and hence patients’ quality of life.
The Pancreatic Cancer Early Detection (PRECEDE) Study is a Global Effort to Drive Early Detection: Baseline Imaging Findings in High-Risk Individuals
Haimi, Ido, Sanoba, Shenin A. , Wang, Yifan , Farrell, James J. , Klute, Kelsey , Bi, Yan , Wallace, Michael B. , Kwon, Richard S. , Sussman, Daniel A. , Merchant, Nipun B. , Golan, Talia , Raitses‐Gurevich, Maria , Lowy, Andrew M. , Liau, Joy , Jeter, Joanne, Lindberg, James , Chung, Daniel C. , Earl, Julie , Brentnall, Teresa A. , Huang, Chenchan , Smerdon, Caroline , Graff, John J., Kastrinos, Fay , _, _, Wallace, Michael B , Zogopoulos, George , Everett, Jessica N. , Katona, Bryson W , Grossberg, Aaron J. , Paiella, Salvatore , Stoffel, Elena M. , Wadlow, Raymond Couric , Permuth, Jennifer B. , Jeter, Joanne , Schrader, Kasmintan A. , Kaul, Vivek , Chandarana, Hersh , Kupfer, Sonia S. , Lucas, Aimee Lee , Sears, Rosalie C. , Brand, Randall E. , Parmigiani, Giovanni , Simeone, Diane M. , _, _

Mayo Clinic

Journal of the National Comprehensive Cancer Network | April 16, 2024 | Volume: 22 | Issue: 3 | Pages: 158-166

10.6004/jnccn.2023.7097 | PMID 38626807 Get It

Background: Pancreatic adenocarcinoma (PC) is a highly lethal malignancy with a survival rate of only 12%. Surveillance is recommended for high-risk individuals (HRIs), but it is not widely adopted. To address this unmet clinical need and drive early diagnosis research, we established the Pancreatic Cancer Early Detection (PRECEDE) Consortium. Methods: PRECEDE is a multi-institutional international collaboration that has undertaken an observational prospective cohort study. Individuals (aged 18–90 years) are enrolled into 1 of 7 cohorts based on family history and pathogenic germline variant (PGV) status. From April 1, 2020, to November 21, 2022, a total of 3,402 participants were enrolled in 1 of 7 study cohorts, with 1,759 (51.7%) meeting criteria for the highest-risk cohort (Cohort 1). Cohort 1 HRIs underwent germline testing and pancreas imaging by MRI/MR-cholangiopancreatography or endoscopic ultrasound. Results: A total of 1,400 participants in Cohort 1 (79.6%) had completed baseline imaging and were subclassified into 3 groups based on familial PC (FPC; n=670), a PGV and FPC (PGV+/FPC+; n=115), and a PGV with a pedigree that does not meet FPC criteria (PGV+/FPC–; n=615). One HRI was diagnosed with stage IIB PC on study entry, and 35.1% of HRIs harbored pancreatic cysts. Increasing age (odds ratio, 1.05; P <.001) and FPC group assignment (odds ratio, 1.57; P <.001; relative to PGV+/FPC–) were independent predictors of harboring a pancreatic cyst. Conclusions: PRECEDE provides infrastructure support to increase access to clinical surveillance for HRIs worldwide, while aiming to drive early PC detection advancements through longitudinal standardized clinical data, imaging, and biospecimen captures. Increased cyst prevalence in HRIs with FPC suggests that FPC may infer distinct biological processes. To enable the development of PC surveillance approaches better tailored to risk category, we recommend adoption of subclassification of HRIs into FPC, PGV+/FPC+, and PGV+/FPC– risk groups by surveillance protocols.
Germline cis variant determines epigenetic regulation of the anti-cancer drug metabolism gene dihydropyrimidine dehydrogenase (DPYD)
Zhang, Ting , Ambrodji, Alisa , Huang, Huixing, Bouchonville, Kelly J. , Etheridge, Amy S. , Schmidt, Remington E. , Bembenek, Brianna M. , Temesgen, Zoey B., Wang, Zhiquan , Innocenti, Federico , Diasio, Robert B. , Stroka, Deborah , Largiadèr, Carlo R. , Offer, Steven M. , Wang, Zhiquan

Mayo Clinic

No container title available | April 16, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.94075.2 Get It

Abstract Enhancers are critical for regulating tissue-specific gene expression, and genetic variants within enhancer regions have been suggested to contribute to various cancer-related processes, including therapeutic resistance. However, the precise mechanisms remain elusive. Using a well-defined drug-gene pair, we identified an enhancer region for dihydropyrimidine dehydrogenase (DPD, DPYD gene) expression that is relevant to the metabolism of the anti-cancer drug 5-fluorouracil (5-FU). Using reporter systems, CRISPR genome edited cell models, and human liver specimens, we demonstrated in vitro and vivo that genotype status for the common germline variant (rs4294451; 27% global minor allele frequency) located within this novel enhancer controls DPYD transcription and alters resistance to 5-FU. The variant genotype increases recruitment of the transcription factor CEBPB to the enhancer and alters the level of direct interactions between the enhancer and DPYD promoter. Our data provide insight into the regulatory mechanisms controlling sensitivity and resistance to 5-FU.
Insulin Signaling Differentially Regulates the Trafficking of Insulin and Amyloid Beta Peptides at the Blood–Brain Barrier
Zhou, Andrew L. , Swaminathan, Suresh Kumar, Salian, Vrishali S. , Wang, Lushan , Curran, Geoffry L., Min, Hoon‐Ki , Lowe, Val J. , Kandimalla, Karunya K. , Min, Hoon-Ki Paul , Kandimalla, Karunya K , Salian, Vrishali

Mayo Clinic

Molecular Pharmaceutics | April 16, 2024 | Volume: 21 | Issue: 5 | Pages: 2176-2186

10.1021/acs.molpharmaceut.3c00784 | PMID 38625027 Get It

Cell Senescence in Heterotopic Ossification
Pignolo, Robert J. , Wang, Haitao , Wang, Haitao , Kaplan, Frederick S.

Mayo Clinic

Biomolecules | April 16, 2024 | Volume: 14 | Issue: 4 | Pages: 485

10.3390/biom14040485 | PMID 38672501 Get It

The formation of bone outside the normal skeleton, or heterotopic ossification (HO), occurs through genetic and acquired mechanisms. Fibrodysplasia ossificans progressiva (FOP), the most devastating genetic condition of HO, is due to mutations in the ACVR1/ALK2 gene and is relentlessly progressive. Acquired HO is mostly precipitated by injury or orthopedic surgical procedures but can also be associated with certain conditions related to aging. Cellular senescence is a hallmark of aging and thought to be a tumor-suppressive mechanism with characteristic features such as irreversible growth arrest, apoptosis resistance, and an inflammatory senescence-associated secretory phenotype (SASP). Here, we review possible roles for cellular senescence in HO and how targeting senescent cells may provide new therapeutic approaches to both FOP and acquired forms of HO.
CircBCL2L13 attenuates cardiomyocyte oxidative stress and apoptosis in cardiac ischemia‒reperfusion injury via miR‐1246/PEG3 signaling
Wu, Hua , Li, Hairui , Song, Jia , Chen, Yongbin , Wang, Ze‐Mu , Jiang, Weipeng , Jiang, Weipeng , Wu, Hua, Zhang, Qian

Mayo Clinic

Journal of Biochemical and Molecular Toxicology | April 12, 2024 | Volume: 38 | Issue: 4 | Pages: No page available

10.1002/jbt.23711 | PMID 38605443 Get It

AbstractIschemia‒reperfusion (I/R) is a common complication in the clinical treatment of acute myocardial infarction (MI), in which cardiomyocytes play a pivotal role in the recovery of cardiac function after reperfusion injury. The expression of numerous circular ribonucleic acids (circRNAs) is disrupted in I/R‐induced cardiac damage, but the potential role of circRNAs in I/R damage has not been fully elucidated. The purpose of the present study was to clarify the biological action and molecular mechanism of circRNA 002166 (also termed circCL2L13) in postmyocardial I/R. Oxygen–glucose deprivation/reoxygenation (OGD/R) in an in vivo model was performed to simulate I/R damage. real‐time polymerase chain reaction analysis was also conducted to evaluate the relationships of the SOD1, SOD2, NRF2, HO1 and GPX4 indicators with oxidative stress injury. TUNEL immunofluorescence was used to evaluate the degree of cardiomyocyte apoptosis in the different treatment groups. The circBCL2L13 level was markedly upregulated in myocardial tissues from a mouse I/R model. Overexpression of circBCL2L13 markedly attenuated the expression of oxidative stress‐related genes and apoptosis in OGD/R‐induced cardiomyocytes. A mechanistic study revealed that circBCL2L13 functions as a ceRNA for miR‐1246 and modulates paternally expressed gene 3 (PEG3). Eventually, circBCL2L13 was proven to regulate PEG3 by targeting miR‐1246, thereby protecting against OGD/R‐induced cardiomyocyte oxidative damage and apoptosis. In conclusion, our study confirmed that the circBCL2L13/miR‐1246/PEG3 axis suppressed the progression of OGD/R injury in cardiomyocytes, which might lead to new therapeutic strategies for cardiac I/R injury.